Chemoprevention of prostate cancer

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 127-136

  Rittmaster, Roger S ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ASCORBIC ACID; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TOREMIFENE;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; DRUG EFFICACY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HORMONAL REGULATION; HUMAN; HYPOGONADISM; IMPOTENCE; INFLAMMATION; LIBIDO DISORDER; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; URINARY TRACT INFECTION; URINE RETENTION;

EID: 79957449340     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.527367     Document Type: Review

References (54)

1. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo 1994;8:439-43.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics CA Cancer J Clin 2010 Jul 7.
3. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med 2009;360:1310-9.
4. Rittmaster RS, Fleshner NE, Thompson IM. Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol 2009;55:1064-73.
5. Nelson WG. Prostate cancer prevention. Curr Opin Urol 2007;17:157-67. (Pubitemid 46597435)
6. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233-44.
7. Ricke WA, Wang Y, Cunha GR. Steroid hormones and carcinogenesis of the prostate: The role of estrogens. Differentiation 2007;75:871-82. (Pubitemid 350086172)
8. Prostate disease trial to study 3,000 MTOPS. Clinical Operations Dept News Release. 1996.
9. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
10. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of Selenium and Vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2008 Dec 9.
11. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians ' Health Study II randomized controlled trial. JAMA 2009;301:52-62.
12. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, et al. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2006;15:1479-84. (Pubitemid 44299319)
13. Grino PB, Griffi n JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126: 1165-72. (Pubitemid 20079537)
14. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996;98:2558-63. (Pubitemid 26415076)
15. W right AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5alpha-reductase. Endocrinology 1999;140: 4509-15. (Pubitemid 30666115)
16. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase defi ciency. J Clin Endocrinol Metab 1992;75:1022-6.
17. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for fi nasteride therapy of prostate carcinoma. Prostate 2003;57:134-9. (Pubitemid 37204494)
18. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008;53:244-52. (Pubitemid 350296595)
19. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010;28:9-15.
20. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995;16:150-63.
21. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The infl uence of fi nasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-24. (Pubitemid 36859473)
22. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of fi nasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33. (Pubitemid 44288787)
23. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-52. (Pubitemid 46560657)
24. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83. (Pubitemid 351767184)
25. Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Infl uence of prostate volume in the detection of prostate cancer. Urology 2003;61:167-71. (Pubitemid 36151735)
26. Serfl ing R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 2007, 177, 2352-6. (Pubitemid 46726388)
27. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of fi nasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74. (Pubitemid 351767189)
28. Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, et al. PCPT: Evidence that fi nasteride reduces risk of most frequently detected intermediate-and high-grade (Gleason score 6 and 7) cancer. Urology 2009;73:935-9.
29. Pinsky P, Parnes H, Ford L. Estimating rates of true highgrade disease in the Prostate Cancer Prevention Trial. Cancer Prevent Res 2008;1:182-6.
30. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prevent Res 2008;1:182-6.
31. Walsh PC. Re: The Prostate Cancer Prevention Trial: Design, biases and interpretation of study results. Goodman PJ, Thompson IM, Jr., Tangen CM, Crowley JJ, Ford LG, Coltman CA, Jr., J Urol 2006;175:2234-42. J Urol 2006;176:2744; author reply.
32. Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high-grade compared to low-grade prostate cancer. J Urol. 2008, 179, 147-51. (Pubitemid 350216746)
33. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537-41.
34. Andriole G, Bautista M, Crawford D, Kusec J, McConnell JD, Lucia S, et al. Prostate cancer (CAP) detection in the medical therapy of prostatic symptoms (MTOPS) trial. J Urol 2003;169:120 Abstract.
35. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with fi nasteride preserves usefulness of prostate-specifi c antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar long-term effi cacy and safety study. Urology 1998;52:195-201.
36. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-7. (Pubitemid 39249705)
37. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
38. Choo R, Danjoux C, Morton G, Szumacher E, Sugar L, Gardner S, et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007;67:1614-20. (Pubitemid 350036947)
39. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
40. Andriole G, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study. J Urol 2011 (in press).
41. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007;178:107-9; Discussion 10.
42. Rittmaster R, Montorsi F, Marberger M, Roehrborn C, Andriole G, Somerville M, et al. Reduction in surgical and non-surgical interventions for prostate cancer with dutasteride treatment in the REduction by DUtasteride of prostate Cancer Events (REDUCE) Study (abstract). Eur Soc Med Oncol 2010 Milan.
43. Nickel JC. Comparison of clinical trials with fi nasteride and dutasteride. Rev Urol 2004;6(Suppl 9):S31-S9.
44. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Jr., Langley C, Ankerst DP, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025-35. (Pubitemid 47232603)
45. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: Results of 4-year studies. BJU Int 2005;96:572-7. (Pubitemid 41224329)
46. S chroder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels 3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol, 2008, 53, 901-8.
47. Schroder FH, Roobol MJ, Andriole GL, Fleshner N. Defi ning increased future risk for prostate cancer: Evidence from a population based screening cohort. J Urol 2009;181:69-74; Discussion.
48. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving fi nasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007;25:3076-81. (Pubitemid 47218054)
49. Andriole G, Rittmaster RS. Dutasteride and prostate cancer [letter to the editor]. N Engl J Med 2010;363:794-5.
50. Walsh PC. Effect of dutasteride on the risk of prostate cancer [editorial]. J Urol. 2010;194:174-5.
51. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: Progress andpromise. Cancer Epidemiol Biomarkers Prev 2007;16: 2193-203. (Pubitemid 351196348)
52. Platz EA. Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2175-80. (Pubitemid 351196344)
53. D'Amico AV. Statin use and the risk of prostate-specifi c antigen recurrence after radiation therapy with or withouthormone therapy for prostate cancer. J Clin Oncol 2010; 28:2651-2.
54. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, et al. Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007;28:763-9. (Pubitemid 47499254)